Coding Mandates and a New State Procurement Channel: Egypt's 2025 Regulatory Reset for Pharmaceuticals

Egypt's pharmaceutical sector runs on a dense framework administered chiefly by the Egyptian Drug Authority, which governs registration, pricing, and inspection, with public buying increasingly funnelled through the Unified Procurement Authority. During 2025 two instruments materially changed the obligations of manufacturers, importers, and distributors. Companies that fail to absorb them risk being unable to circulate product, or to supply the State at all.

The first is Decree No. 161 of 2025, issued by the Chairman of the Egyptian Drug Authority on 29 April 2025. It mandates a unified coding and traceability system across all pharmaceuticals and medical supplies on the Egyptian market, whether locally made or imported, and reaches every party involved in production, distribution, and storage. Each product must carry a two-dimensional barcode built to international standards and encoding four data points: the product's individual identification number, its expiry date, the batch number, and a randomised serial number. For medical supplies handled on the dedicated device platform, the decree swaps the earlier barcode rule for approval from bodies recognised by the International Medical Device Regulators Forum. The decree was set to take effect the day after the Authority published its implementing guidance, expected within fifteen working days of issuance.

The legal weight of Decree No. 161 is direct. Products not registered under the approved coding system cannot lawfully circulate in Egypt, which turns a technical labelling rule into a condition of market access. Manufacturers must confirm that their serialisation infrastructure, packaging lines, and data systems generate compliant codes, while importers must ensure foreign suppliers apply the required identifiers before goods reach Egyptian customs. Distributors and storage operators fall squarely within scope as well, so supply-chain contracts should be reviewed to allocate responsibility for compliance and to build in remedies where a counterparty's failure threatens the saleability of stock. The regime also sharpens the Authority's tools against counterfeit and diverted product, an enforcement priority companies should expect to see reflected in inspections.

The second instrument reshapes how the sector sells to the State. The Ministry of Finance issued Circular No. 94 of 2025 on 24 November 2025, establishing a contracting mechanism for public-sector procurement of pharmaceuticals and medical supplies, with effect from 1 July 2025. Procurement must now proceed through a three-party structure linking the Unified Procurement Authority, the requesting public entity, and the supplier. Public requestors submit their requests to the Authority, which takes the necessary steps and issues purchase orders in favour of those requestors, while suppliers deliver directly to them. Requestors pay suppliers for what they receive and separately settle the Authority's fees, handing payment documentation to the Authority for oversight. The framework applies to bodies governed by Law No. 151 of 2019, and arrangements concluded before 1 July 2025 stay under the prior circular.

For suppliers, the upshot is that government contracting now runs through a defined three-party channel, with the Authority positioned as coordinator and fee-collector rather than as the single central buyer in every transaction. Reporting around the change indicates the Authority's role was deliberately narrowed to oversight and monitoring following a presidential directive in September 2025, against a backdrop of accumulated public-sector debts to suppliers and persistent medicine shortages. The State moved to relieve that pressure, with reports of some eleven billion Egyptian pounds released to settle overdue pharmaceutical dues. Companies tendering to government hospitals and public health entities should revisit their contract templates, their grasp of who bears payment risk, and their fee assumptions, and should treat receivables management with the public sector as a live legal and commercial risk rather than an administrative formality.

Underlying both instruments is the unresolved question of drug pricing. The compulsory pricing regime continues to bite at every level of the chain, and through 2025 manufacturers pressed for either lower Authority service fees or an across-the-board price adjustment, citing products sold below production cost and shortages that fed black-market activity. Any pricing reform that emerges will interact with the coding and procurement frameworks above, since traceability data and procurement records increasingly evidence the real economics of each product. The Authority has meanwhile signalled wider ambitions, exploring a pan-African digital platform to widen access to medicines.

The regional contrast is modest but instructive. The United Arab Emirates tightened the substance and audit conditions attached to free-zone tax benefits during 2025. The common thread for businesses operating across Egypt and the UAE is that regulatory privilege, whether market access or favourable tax treatment, now turns on demonstrable, auditable adherence to detailed procedural rules. In Egypt specifically, serialisation readiness and procurement-channel compliance are the two near-term priorities legal and regulatory teams should resolve before they translate into lost sales.